On 9th February 2019, the European Falsified Medicine Directive (FMD) went into effect. PHOENIX group is taking this topic very seriously and has carefully prepared for the implementation in all business areas.
The FMD requires the placement of safety features consisting of a unique identifier and an anti-tampering device on the packaging of certain medicinal products for human use for the purposes of allowing their identification and authentication. The aim of FMD is to prevent falsified medicines from entering the pharmaceutical supply chain.
We from PHOENIX group see FMD as an essential step forward towards ensuring patient safety. Therefore, for several months, our dedicated team has been diligently and pro-actively working on the FMD implementation plan by developing a central FMD cloud-based solution. FMD is implemented in all of our business areas (Healthcare Logistics, Wholesale, Pharmacies and GMP-related activities) in the impacted countries. We are therefore fully compliant with the legislation and are ready to contribute in the authentication of medicinal products that reach patients – in every market!